|Dr. Roger James Pomerantz FACP, M.D., F.A.C.P.||Chairman, CEO & Pres||1.37M||N/A||1957|
|Mr. Michael Messinger CPA, CPA||Chief Financial Officer||623.3k||N/A||1975|
|Dr. Cara M. Cassino||Chief Medical Officer and Exec. VP of R&D||883.15k||N/A||1962|
|Ms. Natalie Bogdanos J.D.||Gen. Counsel, Corp. Sec. & Data Protection Officer||N/A||N/A||1969|
|Dr. Gary Woodnutt||Sr. VP of Translational Sciences & Preclinical Devel.||N/A||N/A||1957|
|Dr. Michael Wittekind||Consultant||N/A||N/A||1955|
ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staph aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which in preclinical trials for the treatment of pseudomonas aeruginosa infections, including ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. The company has a collaboration research agreement with The Rockefeller University to identification of novel lysin therapeutic candidates targeting gram-negative pathogens. It also initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus in COVID-19 patients. The company was incorporated in 2008 and is headquartered in Yonkers, New York.
ContraFect Corporation’s ISS Governance QualityScore as of July 1, 2021 is 8. The pillar scores are Audit: 3; Board: 7; Shareholder Rights: 6; Compensation: 10.